<DOC>
	<DOCNO>NCT00318669</DOCNO>
	<brief_summary>This study design evaluate efficacy safety Social Anxiety Disorder ( SAD ) .</brief_summary>
	<brief_title>Social Anxiety Disorder Study Of Paroxetine</brief_title>
	<detailed_description />
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>Inclusion criterion : Diagnosis Social Anxiety Disorder ( SAD ) ( 300.23 Social Phobia/Social Anxiety Disorder ) accord DSMIVTR criterion . Must give write informed consent . But patient 20 , patient himself/herself his/her proxy consenter must give write informed consent . Patients minimum score 60 LSAS total score . Exclusion criterion : Patients primarily diagnose disorder categorize Axis I exclude SAD DSMIVTR ( e.g . major depression , dysthymic disorder , specific phobia ( simple phobia ) , obsessive compulsive disorder , panic disorder ) within 24weeks week 2 . Patients history complication schizophrenia bipolar disorder Patients complication body dysmorphic disorder . Patients evidence substance abuse ( alcohol drug ) substance dependence DSMIVTR criterion within 24 week week 2 . Patients start psychotherapy cognitivebehavioural therapy within 24 week week2 , except supportive psychotherapy . Patients receive electroconvulsive therapy ( ECT ) within 12 week week 2 . Patients pregnant , lactate childbearing potential likely become pregnant . Patients 3 point HAMD Item No . 3 , likely attempt suicide . Patients history complication cancer malignant tumor . Patients receive MAO inhibitor ( FPÂ® ) within 14 day expect week 0 visit date .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Anxiety</keyword>
	<keyword>SAD</keyword>
	<keyword>Social</keyword>
	<keyword>Disorder</keyword>
</DOC>